Brought to you by 
MIODx licenses immunotherapy technologies from UCSF
02 May 2017
Executive Summary
University of California, San Francisco granted MIODx exclusive rights to two immunotherapy technologies for use in patient monitoring and companion diagnostics.
Deal Industry
- In Vitro Diagnostics
- Services
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
Pharmaceuticals
- Vaccines
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Therapeutic Drug Monitoring
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MIODx licenses immunotherapy technologies from UCSF
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice